Physician and Media Personality Dr. Drew Pinsky, Dr. Drew, Joins Aditx Therapeutics as Senior Advisor to AditxtScore™ for S...
September 10 2020 - 7:51AM
via NEWMEDIAWIRE -- Aditx Therapeutics, Inc. (Aditxt)
(the “Company”) (Nasdaq: ADTX), a life sciences company
developing biotechnologies specifically focused on improving the
health of the immune system through immune monitoring and
reprogramming, today announced that it has appointed Dr. Drew as
Senior Advisor, AditxtScore™, effective September 1, 2020.
Dr. Drew, a practicing physician, internist, and
an addiction medicine specialist, will advise on the development of
AditxtScore™ platform, and its various potential applications
including possibly scoring immunity to COVID-19 and other
infectious diseases, as well as autoimmune disorders such as Type I
Diabetes.
And as a well-known American media personality,
Dr. Drew will act as brand ambassador as he advises on the overall
marketing and deployment strategies of AditxtScore™. He
will also assist in the planning and introduction of the platform
and its applications for the medical and consumer markets.
Amro Albanna, Co-Founder and Chief Executive
Officer of Aditxt, stated, “Dr. Drew is a key addition to our
leadership team and I am very proud that he will become a part of
our journey. I believe Dr. Drew’s scientific, medical,
and media background will make him a great fit for executing our
vision for AditxtScore. With today’s announcement and
the ones we recently made, I believe the market will begin to see
how we are laying a strong foundation necessary for commercializing
our therapeutics as well as our immune monitoring
biotechnologies.”
Dr. Pinsky added,“I believe that the AditxtScore
platform could be game changing because it has the ability to alter
how we keep abreast of changes in our immune system. The initial
focus will be to further develop AditxtScore for COVID-19 to try to
detect vaccine-induced or natural immunity to COVID-19 and other
infectious agents. I believe knowing whether or not
someone is infected simply isn’t enough. We must work to be
able to evaluate someone’s immune status in order to make informed
decisions as we reopen the global economy. I look
forward to working with the team at Aditxt and contributing to the
development and roll out of the AditxtScore platform.”
Dr. Drew is a diplomat of the American Board
of Internal Medicine, the American Board of Addiction Medicine, and
a fellow with the American College of Physicians (FACP). He has
been appointed to the Alpha Omega Alpha Honor Medical Society and
is also a member of the board for the Prostate Cancer
Foundation.
He began his media career while attending medical
school in 1984 and is known for his work on radio, television, and
podcasts. He is also the author of the New York Times
bestseller “The Mirror Effect: How Celebrity Narcissism is
Seducing America”, and “Cracked: Putting Broken Lives Together
Again”. Dr. Drew co-authored the first academic study on
celebrities and narcissism, which was published in the Journal of
Research in Personality (Elsevier) and received worldwide press
coverage. Dr. Drew has an undergraduate degree in biology
from Amherst College and earned his Doctor of Medicine degree from
the University of Southern California School of Medicine.
About Aditx Therapeutics
Aditxt is developing technologies specifically
focused on improving the health of the immune system through immune
monitoring and reprogramming. The immune monitoring technology is
designed to provide a personalized comprehensive profile of the
immune system. The immune reprogramming technology is currently at
the pre-clinical stage and is designed to retrain the immune system
to induce tolerance with an objective of addressing rejection of
transplanted organs, autoimmune diseases, and allergies. For more
information, please visit: www.aditxt.com
Forward-Looking Statements
Certain statements in this press release by Aditxt
and/or Dr. Drew Pinsky constitute “forward-looking statements”
within the meaning of the federal securities laws. Forward looking
statements include statements regarding the Company’s intentions,
beliefs, projections, outlook, analyses or current expectations
concerning, among other things, the Company’s ongoing and planned
product development; the Company’s intellectual property position;
the Company’s ability to develop commercial functions; expectations
regarding product launch and revenue; the Company’s results of
operations, cash needs, spending, financial condition, liquidity,
prospects, growth and strategies; the industry in which the Company
operates; and the trends that may affect the industry or the
Company. Forward-looking statements are not guarantees of future
performance and actual results may differ materially from those
indicated by these forward-looking statements as a result of
various important factors, as well as those risks more fully
discussed in the section entitled “Risk Factors” in the
Company’s prospectus, dated September 1, 2020, that was filed with
the U.S. Securities and Exchange Commission under File No.
333-248491, as well as discussions of potential risks,
uncertainties, and other important factors in the Company’s
subsequent filings with the U.S. Securities and Exchange
Commission. All such statements speak only as of the date made, and
neither the Company or Dr. Drew Pinsky undertakes any obligation to
update or revise publicly any forward-looking statements, whether
as a result of new information, future events or otherwise.
Investor Relations:
PCG AdvisoryJeff RamsonChief Executive
OfficerIR@aditxt.com 646-762-4518www.aditxt.com
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Apr 2024 to May 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From May 2023 to May 2024